Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2008

View Archived Issues

HSV-2 vaccine dl5-29 effective in HSV-1 seropositive guinea pigs

Recent patents disclose new anticancer agents

G-CSF-induced neuroprotection in mouse models of ALS

Avir commences phase I study for intranasal pandemic influenza vaccine deltaFLU

Proellex reduces pain in phase II clinical trial in moderate to severe endometriosis

GlobeImmune collaborates with the NIH to develop cancer therapeutics

Targeting CaMKK2 may be useful for the treatment of obesity and diabetes

Novartis enters strategic partnership with Lonza to accelerate its biologics pipeline

Study shows bioequivalence between Insmed's INS-19 and Neupogen

Novel analgesic agents described in recent patent literature

Proteolix initiates dosing in phase Ib clinical trial of proteasome inhibitor carfilzomib

Promising preclinical results with STF-62247 in treating renal cell carcinoma

DSMB recommends discontinuation of vaccinations in phase III TRIST study of TroVax

Recent Exelixis and Nippon Zoki patents report new treatment options for metabolic disorders

Pharming reports positive results from open-label studies of Rhucin in HAE

Napo reports results from phase IIa and IIb trials of crofelemer in D-IBS

NeurogesX initiates phase I clinical trial of NGX-1998 for neuropathic pain

Nile Therapeutics initiates dosing in phase IIa clinical study of CD-NP in heart failure

Alcon terminates development of anecortave acetate in AMD

Actelion and GSK collaborate on almorexant in sleep disorders

Tredaptive approved in E.U. for dyslipidemia and primary hypercholesterolemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...